None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL (2014) J Clin Oncol 32(12): 1202-9
    › Primary publication · 24663045 (PubMed) · PMC3986383 (PubMed Central)
  2. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) Clin Cancer Res 20(4): 782-90
    › Primary publication · 24536073 (PubMed) · PMC3962777 (PubMed Central)
  3. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE (2014) Magn Reson Med 71(4): 1592-602
    › Primary publication · 23661583 (PubMed) · PMC3742614 (PubMed Central)
  4. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Abramson VG, Mayer IA (2012) Ther Adv Med Oncol 4(3): 139-47
    › Primary publication · 22590487 (PubMed) · PMC3349077 (PubMed Central)
  5. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Abramson V, Arteaga CL (2011) Clin Cancer Res 17(5): 952-8
    › Primary publication · 21248299 (PubMed) · PMC3761872 (PubMed Central)
  6. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A (2010) Anticancer Res 30(4): 1279-85
    › Primary publication · 20530440 (PubMed) · PMC3874215 (PubMed Central)